Why it matters 👉 FASN-driven lipogenesis, CD36-mediated FA uptake & CPT1A-powered FAO fuel anti-HER2 escape. Targeting lipid metabolism + HER2 therapy = a powerful combo in the making. #LipidMetabolism #TranslationalResearch #PrecisionOncology #BreastCancer

We map trastuzumab resistance into 3 metabolic hallmarks:.1️⃣ Metabolic reprogramming.2️⃣ Adaptive stress responses.3️⃣ Metabolic–signaling crosstalk.A clear roadmap to expose vulnerabilities & re-sensitize tumors to HER2 blockade. #CancerMetabolism #OncoTargets

Our latest article in @ExpertOpinionTgt decodes the #metabolic hallmarks behind #trastuzumab resistance in #HER2-positive #BreastCancer. Discover how metabolic rewiring drives therapeutic escape. Read here ➡️ @ProcureICO @idibgi @ICO_oncologia.

RT @idibgi: 🔬Un estudi de l'@idibgi i l'@ICO_oncologia identifica una proteïna clau en la resposta a les teràpies 'un-dos' en oncologia. L….

Un estudio identifica una proteína clave en la respuesta a las terapias

"1-2 punch": Contrary to the idea that all #senescent cells are highly apoptotic, we find therapy-induced senescent #cancer cells vary greatly in their ‘mitochondrial #priming’ but rely on BCL-xL for survival. @ProcureICO @idibgi @ICO_oncologia

RT @ICO_oncologia: 🔬Un estudi de l'@ICO_oncologia i l'@idibgi identifica una #proteïna clau per millorar la resposta a les teràpies ‘un-dos….

New insigths on therapy-induced #senescence (TIS). Senescent #cancer cells can be unprimed for #apoptosis yet still vulnerable to BCL-xL-targeted pro-apoptotics. BCL-xL is a key #senolytic target in "one-two punch". @ProcureICO @ICO_oncologia @idibgi

Excited and proud to see our PhD student @mediuenAngela in Amsterdam, presenting our latest results on anti-lipogenic #cancer therapy and cancer cell #senescence at the Young ICSA Symposium @YicsaC . @idibgi @ProcureICO

The dense #PancreaticCancer stroma obligates metabolic reprogramming of tumor cells. Targeting #FattyAcidSynthase push them toward the cliff’s edge of dying. A rationale for #PDAC chemo-metabolic therapies. @ProcureICO @silviaosu @idibgi @ICO_oncologia

RT @ICO_oncologia: Un estudi de l’@ICO_oncologia i @idibgi identifica una nova teràpia combinada per al #càncer de #pàncrees. Aquesta com….

RT @idibgi: 📢 Un estudi de l’@ICO_oncologia -IDIBGI identifica una nova teràpia combinada per al càncer de pàncrees. Llegeix-ne més 👉 http….

#PancreaticCancer cells adapt to a nutrient-poor environment by rewiring their #metabolism. Blocking their "fat factory" pushes them to the brink of #apoptosis & makes them highly sensitive to BH3 mimetics. @ProcureICO @ICO_oncologia @idibgi @IQCCUdG

RT @ICO_oncologia: Nova diana en la #immunoteràpia del #càncer .Segons l'estudi @ICO_oncologia i @idibgi el bloqueig de la sintasa d’àcids….

RT @idibgi: 🛑La recerca demostra que la interrupció del funcionament de la FASN redueix la capacitat de les cèl·lules tumorals per defensar….

RT @idibgi: 🔬Un estudi del grup de Metabolisme i Càncer (IDIBGI- @ICO_oncologia ) descriu per primera vegada el paper clau de la sintasa d’….

RT @Biotech_Spain: .@idibgi La sintasa de ácidos grasos (FASN): Una nueva diana en la inmunoterapia contra el cáncer .

Fatty Acid Synthase (FASN): A new target to boost cancer immunotherapy a través de @idibgi @ProcureICO @ICO_oncologia.

La sintasa d’àcids grassos (FASN): Una nova diana en la immunoteràpia contra el cáncer a través de @idibgi @ProcureICO @ICO_oncologia.